Ananthesh L

Publication Activity (10 Years)

Years Active: 2022-2022
Publications (10 Years): 5

Top Topics

Coronavirus Disease

Cross Sectional

Top Venues

This page only lists publications with an associated author ORCID identifier.

Publications

Akshay Ayappan, Bijaya Kumar Padhi, Ananthesh L, Raushan Kumar Chaudhary, Uday Venkat Mateti, Adithi Kellarai, Mazhuvanchery Kesavan Unnikrishnan, Jaclyn Drishal Dsouza, Ali Davod Parsa, Russell Kabir, Ranjit Sah
Perception of Availability, Accessibility, and Affordability of COVID-19 Vaccines and Hesitancy: A Cross-Sectional Study in India. Vaccines 10 (12) (2022)
Akshay Ayappan, Bijaya Kumar Padhi, Ananthesh L, Raushan Kumar Chaudhary, Uday Venkat Mateti, Adithi Kellarai, Mazhuvanchery Kesavan Unnikrishnan, Jaclyn Drishal Dsouza, Ali Davod Parsa, Russell Kabir, Ranjit Sah
Perception of Availability, Accessibility, and Affordability of COVID-19 Vaccines and Hesitancy: A Cross-Sectional Study in India. Vaccines 10 (12) (2022)
Akshay Ayappan, Bijaya Kumar Padhi, Ananthesh L, Raushan Kumar Chaudhary, Uday Venkat Mateti, Adithi Kellarai, Mazhuvanchery Kesavan Unnikrishnan, Jaclyn Drishal Dsouza, Ali Davod Parsa, Russell Kabir, Ranjit Sah
Perception of Availability, Accessibility, and Affordability of COVID-19 Vaccines and Hesitancy: A Cross-Sectional Study in India. Vaccines 10 (12) (2022)
Akshay Ayappan, Bijaya Kumar Padhi, Ananthesh L, Raushan Kumar Chaudhary, Uday Venkat Mateti, Adithi Kellarai, Mazhuvanchery Kesavan Unnikrishnan, Jaclyn Drishal Dsouza, Ali Davod Parsa, Russell Kabir, Ranjit Sah
Perception of Availability, Accessibility, and Affordability of COVID-19 Vaccines and Hesitancy: A Cross-Sectional Study in India. Vaccines 10 (12) (2022)
Akshay Ayappan, Bijaya Kumar Padhi, Ananthesh L, Raushan Kumar Chaudhary, Uday Venkat Mateti, Adithi Kellarai, Mazhuvanchery Kesavan Unnikrishnan, Jaclyn Drishal Dsouza, Ali Davod Parsa, Russell Kabir, Ranjit Sah
Perception of Availability, Accessibility, and Affordability of COVID-19 Vaccines and Hesitancy: A Cross-Sectional Study in India. Vaccines 10 (12) (2022)